SCYNEXIS (SCYX)
NASDAQ:SCYX
Want to see SCYX full AI Analyst Report?
SCYX Stock Chart & Stats
$0.66
-$0.06(-4.73%)
At close: 4:00 PM EST
$0.66
-$0.06(-4.73%)
Day’s Range― - ―
52-Week Range$0.57 - $1.31
Previous CloseN/A
Volume100.07K
Average Volume (3M)612.75K
Market Cap
$79.44M
Enterprise Value$24.95M
Total Cash (Recent Filing)$40.11M
Total Debt (Recent Filing)$2.17M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
May 18, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.25
Shares Outstanding79,442,635
10 Day Avg. Volume689,890
30 Day Avg. Volume612,753
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue1.21
Enterprise Value/Gross Profit1.21
Enterprise Value/Ebitda1.52
Forecast
1Y Price Target
$3.50Price Target Upside430.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$1.15M
Bulls Say, Bears Say
Bulls Say
Asset Monetization PotentialMid-stage-ready antifungal candidate SCY-247 could be partnered or divested to generate non-dilutive funding and accelerate other development programs.
Clinical Differentiation And SafetySCY-770 targets autosomal dominant polycystic kidney disease with a different mechanism that could compete with existing therapy while potentially avoiding liver-safety issues.
Pipeline DiversificationAcquisition of SCY-770 shifts company focus into a high-value rare disease area and broadens the development pipeline beyond antifungals.
Bears Say
Analyst Valuation PressureDevelopment and revenue risks have prompted analyst adjustments that could lead to downgrades and increased downward pressure on the stock.
Clinical And Regulatory RiskSCY-770 remains early in clinical development, creating exposure to trial failures and regulatory setbacks that could negatively affect valuation.
Revenue Forecast UncertaintyAnalysts applied meaningful revenue risk adjustments due to uncertainty in translating early clinical results into future commercial sales.
SCYNEXIS News
SCYX FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $0.56 and its highest was $1.31 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $79.44M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is May 18, 2026 which is in 18 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Mar 04, 2026. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.127 by $0.123.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.12.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 79,442,635 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of $0.25 in its last earnings report, beating expectations of $0.127. Following the earnings report the stock price went up 2.194%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in SCYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (430.30% Upside)
$3.50 (430.30% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.87%
12-Months-Change
Fundamentals
Return on Equity
-19.05%
Trailing 12-Months
Asset Growth
-34.88%
Trailing 12-Months
Company Description
SCYNEXIS
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
SCYX Stock 12 Month Forecast
Average Price Target
$3.50
▲(430.30% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―
Ownership Overview
6.18% Insiders
11.39% Mutual Funds
0.23% Other Institutional Investors
78.42% Public Companies and
Individual Investors